Journal
CANCER LETTERS
Volume 313, Issue 2, Pages 137-144Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2011.05.030
Keywords
Pancreatic cancer; Gemcitabine; Salinomycin; Combination treatment
Categories
Funding
- National Laboratory of Molecular Biology Special Foundation [2060204]
Ask authors/readers for more resources
Previous research has documented that a subpopulation of pancreatic cancer cells, named cancer stem cells (CSCs), harbor stem cell-like properties. Here, we examined the efficacy of combined treatments of salinomycin and gemcitabine in human pancreatic cancer cells. Salinomycin inhibited the growth of CSCs, while gemcitabine suppressed the viability of non-CSCs. Consistently, in vivo studies showed that salinomycin combined with gemcitabine could eliminate the engraftment of human pancreatic cancer more effectively than the individual agents. These data indicated that administration of salinomycin, which targets CSCs, may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine to eradicate pancreatic cancer. (C) 2011 Published by Elsevier Ireland Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available